Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non‐Small Cell Lung Cancer

BACKGROUND. Tissue tumor mutational burden (TMB) has emerged as a potential biomarker predicting response to anti‐programmed cell death‐1 protein receptor (PD‐1)/programmed cell death‐1 protein ligand (PD‐L1) therapy, but few studies have explored using circulating tumor DNA (ctDNA) TMB in non‐small...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Chae, Young Kwang, Davis, Andrew A., Agte, Sarita, Pan, Alan, Simon, Nicholas I., Iams, Wade T., Cruz, Marcelo R., Tamragouri, Keerthi, Rhee, Kyunghoon, Mohindra, Nisha, Villaflor, Victoria, Park, Wungki, Lopes, Gilberto, Giles, Francis J.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Immuno‐Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656496/
https://ncbi.nlm.nih.gov/pubmed/30867242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0433
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados